Skip to main content
mLife logoLink to mLife
. 2026 Feb 21;5(1):3–16. doi: 10.1002/mlf2.70068

Prokaryotic defense systems: Diversity and evolutionary adaptation

Changjialian Yang 1,2, Luyao Gong 1, Jing Guo 1, Hua Xiang 1,2,3,
PMCID: PMC12948488  PMID: 41767949

Abstract

Bacteriophages and archaeal viruses are the most abundant biological entities on Earth. Through a long‐standing co‐evolutionary arms race, they have driven the emergence of a diverse repertoire of prokaryotic defense systems. This review summarizes these systems, highlighting their diverse antiviral mechanisms across distinct stages of viral infection, from surface barriers and inducible innate responses to specific adaptive defenses, and the intricate interplay between these defense strategies. By examining host–virus counter defense dynamics, the trade‐off between survival benefit and adaptive cost, the co‐evolution of RNA and protein components, and the comparison with eukaryotic immune systems, we underscore the intrinsic complexity and evolutionary plasticity of prokaryotic antiviral immunity. A deeper understanding of these processes and mechanisms will not only shed light on the origins and evolution of the immune system but also provide valuable opportunities for the development of biotechnological tools.

Keywords: ancestral immunity, defense systems, diversity, evolutionary adaptation, prokaryotes

INTRODUCTION

Bacteriophages and archaeal viruses are among the most abundant biological entities on Earth and show strict host specificity for prokaryotes. The global bacterial population is estimated to be approximately 1030, whereas phage particles are thought to outnumber them by nearly an order of magnitude 1 . Phages greatly enhance horizontal gene transfer (HGT) and drive a long‐standing co‐evolutionary dynamic that has shaped the genomic diversity of bacteria over billions of years.

Prokaryotes have evolved a diverse array of defense systems that disrupt infections at multiple stages 2 . For instance, prokaryotes may block phage recognition or genome injection through surface barriers 3 , 4 , interrupt infection by degrading or blocking the replication of phage genomes through various innate immune systems 5 , 6 , use adaptive immune systems to memorize and rapidly eliminate previously encountered phages 7 , or, if all defense systems fail, trigger abortive infection (Abi) to sacrifice the infected host cell to prevent the further spread of viruses 8 . The evolutionary pressure exerted by phages drives the continuous emergence and maintenance of a broad range of prokaryotic‐defense strategies 9 .

Recent advances in high‐throughput methodologies, computational algorithms, and artificial intelligence have improved the ability to identify and characterize defense systems on a genome‐wide scale. Analysis of bacterial and archaeal defense systems revealed that these systems are frequently associated with mobile genetic elements (MGEs) and usually clustered within specific genomic regions. This has led to the concept of “defense islands,” in which protein families located near known defense genes are likely to belong to novel defense systems or contribute to immune function 10 . Synergistic interactions between defense systems may promote their colocalization within genomes and facilitate HGT across species. Once a few defense systems are known, many more can be identified and characterized across prokaryotes based on sequence homology, structural similarity, and genomic regions 11 , 12 , 13 , 14 . Besides the well‐known clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR‐associated (Cas) system 15 , 16 , recent studies have revealed numerous novel defense systems involving enzymes such as NADases, helicases, ATPases, and deaminases, highlighting the critical role of protein complexes in prokaryotic defense. Notable examples include Septu 17 , Gabija 18 , Thoeris 19 , 20 , restriction by an adenosine deaminase acting on RNA (RADAR) 12 , 21 , DUF4297‐Her 22 , Nezha 23 , Shedu 5 , and Hachiman 24 (Table 1). The rapid expansion of mechanistic studies on these antiphage systems has provided valuable insights into how microbes counter environmental and viral challenges.

Table 1.

Structural and functional characteristics of novel prokaryotic defense systems.

System Mechanism Components Domain Structure Molecular mass References
Septu Degradation of phage genome PtuA, PtuB ATPase, nuclease PtuA‐PtuB complex(6:2) ~380 kDa 17
Gabija Abi induces cell death GajA, GajB ATPase, helicase GajA‐GajB complex(4:4) ~500 kDa 18
Thoeris Abi induces cell death ThsA, ThsB NADase, TIR ThsA tetramer / 19,20
DUF4297‐Her Degradation of phage genome DUF4297, HerA ATPase, helicase HerA‐DUF4297 complex(6:12) ~1 MDa 22
Nezha Degradation of phage genome Sir2, HerA NADase, helicase HerA‐Sir2 complex(6:12) ~1 MDa 23
Shedu Degradation of phage genome SduA Nuclease SduA tetramer / 5
RADAR Inhibition of phage propagation RdrA, RdrB ATPase, adenosine deaminase RdrA‐RdrB complex(7:12 or 14:12) ~10 MDa 12, 21
Hachiman Degradation of host and phage genome HamA, HamB Nuclease, helicase HamA‐HamB complex(1:1) / 24

Abi, Abortion infection; RADAR, restriction by an adenosine deaminase acting on RNA; TIR, Toll/interleukin‐1 receptor.

This review analyzes the diverse mechanisms of prokaryotic defense systems that operate at distinct stages of viral infection and the complex interactions among them. It also highlights the multifaceted evolutionary adaptability of the prokaryotic immune system, emphasizing the intrinsic complexity and dynamic interplay between these systems. By elucidating modular conservation and directional evolution, we uncover previously unrecognized connections and propose a refined framework for understanding the diversity and adaptive capacity of prokaryotic defense systems.

DIVERSITY OF DEFENSE SYSTEMS

Prokaryotes and their viruses (bacteriophages and archaeal viruses) engage in continuous evolutionary competition driven by environmental changes and infection pressure 2 . Over evolutionary time scales, prokaryotes have evolved defense systems that target distinct stages of the viral life cycle, enabling them to adapt to environmental changes and resist foreign invasion.

Defense systems function by interfering with the interactions between phages and prokaryotes, destabilizing viral structural components, and inhibiting phage DNA replication. Escape mutations frequently occur in key phage genes involved in DNA replication, structural assembly, and host takeover mechanisms 25 . Prokaryotes possess an array of defense systems that recognize and eliminate invaders and enhance their resistance to future infection. These defense systems can be broadly categorized into surface barriers, nonspecific intracellular defenses, and specific adaptive defenses (Figure 1).

Figure 1.

Figure 1

Diversity of prokaryotic defense mechanisms. (A) Surface barrier. Its main role is to prevent viral attachment to the host and block the injection of the viral genome. By preventing the virus from entering the cell, this line of defense acts as an initial shield against infection. (B) Nonspecific intracellular defense. This system functions by degrading the genetic material of the invading viruses or preventing their replication. It provides broad, nonspecific protection by targeting a wide range of pathogens without requiring prior exposure. (C) Specific adaptive defense. This system specifically recognizes foreign genetic material based on previous encounters and efficiently targets and eliminates viruses. (D) Abortion infection (Abi). When all other defense systems fail, Abi can act at that point to prevent the spread of infection by inducing cell death.

Surface barriers

Surface barriers play a crucial role in inhibiting viral attachment and genome injection (Figure 2). The barriers to bacteria rely on cell envelope and biofilm formation 4 . The cell membrane contains specific surface receptors that interact with viral receptor‐binding proteins (RBPs). Bacteria use receptor masking, modification, and mutation to block viral attachment. For example, Pseudomonas aeruginosa glycosylates its pili to prevent viral binding 26 . Some phages integrate their genomes into bacterial chromosomes to form prophages encoding defense proteins that alter key membrane components to block subsequent infections. For instance, the prophage D3112 of P. aeruginosa produces proteins that interact with ATPase to inhibit pilus extension 27 . Proteins of the bacterial outer membrane, which maintain membrane stability and participate in diverse biological processes, also contribute to phage defense 28 . Biofilms, which comprise high‐molecular‐weight polymers and other components, form a protective layer that shields bacteria from antibiotics and other invaders. Extracellular vesicles (EVs) or outer membrane vesicles (OMVs) containing surface receptors can act as molecular decoys, diverting phage recognition from the host cell 29 .

Figure 2.

Figure 2

Surface barriers preventing phage attachment and entry. Bacteria block phage binding by modifying their receptors through masking, mutations, or modifications. Outer membrane vesicles (OMVs) can act as decoys to prevent viral recognition and attachment. Some phages integrate their genomes into bacterial chromosomes as prophages, encoding defense genes that modify key cell envelope components to block further phage invasion. Archaea have a proteinaceous S‐layer composed of glycosylated proteins that forms a primary barrier to impede viral attachment and penetration.

Archaea have evolved distinct surface defense mechanisms that rely on specialized cell envelope structures 30 . Unlike bacteria, many archaea are surrounded by a proteinaceous S‐layer composed of glycosylated proteins, which serves as the primary barrier against viral entry by creating a complex surface that impedes viral attachment and penetration 30 , 31 . The diversity of S‐layer protein composition further complicates viral invasion, making it difficult for viruses to recognize and breach the archaeal cell envelopes. In addition, archaeal membranes contain unique lipids that provide an extra layer of defense against viral entry 32 . Filamentous glycans extending from the S‐layer form an additional glycan barrier, collectively establishing a multilayered defense architecture that effectively reduces the likelihood of successful infection 30 .

Nonspecific intracellular defense

After bypassing the surface defenses, viruses inject their genetic material into host cells (Figure 3). Viral genomes, which are typically linear and lack protective DNA‐binding proteins, are particularly vulnerable to broad‐spectrum, intracellular defense systems.

Figure 3.

Figure 3

Key intracellular antiviral defense mechanisms in prokaryotes. (1) Defense‐related protein complex. Large protein complexes composed of enzymes found in defense islands contribute to diverse bacterial‐defense strategies. (2) Restriction–modification system. Foreign DNA is cleaved, whereas modified host DNA is protected through sequence‐specific modification. (3) Argonaute system. Some prokaryotic Argonaute (Ago) proteins cleave small molecules, such as NAD+/NADP+, whereas others are associated with nucleases that degrade nucleic acids in a guide‐dependent or nonspecific manner. (4) Retron system. This system produces cDNA and triggers growth arrest after phage attack. (5) Prophage‐mediated defense. Prophages are genomic elements that use phage components to limit or block their replication. (6) Second‐messenger signaling system. Phage infection induces the production of signaling molecules that trigger effectors, leading to growth arrest, cell death, or inhibition of phage replication. (7) Abortive infection (Abi) system. Infected cells undergo self‐destruction to prevent phage propagation, often in coordination with other defense systems. (8) CRISPR–Cas system. Phage DNA fragments are captured as spacers and later used to guide Cas proteins to destroy future invaders. APAZ, analog of Piwi‐Argonaute‐Zwille; PICI, phage‐inducible chromosomal island; PLE, phage inducible chromosomal islands‐like element; TIR, Toll/interleukin‐1 receptor.

Small‐molecule arsenal

Bacteria can defend themselves against phages using small molecules that interfere with the phage life cycle. For instance, Streptomyces species produce secondary metabolites that block phage replication by intercalating into phage DNA 33 , 34 , 35 . One such example is daunorubicin, a DNA‐intercalating agent 34 . Upon infection, the phage injects its DNA into the host, which then replicates for the propagation of the virus. Daunorubicin intercalates between DNA base pairs, distorting the phage genome and preventing circularization or interaction with essential replication proteins 35 . Consequently, the replication of phage DNA is halted. Another compound, doxorubicin, functions similarly and inhibits the replication of various double‐stranded DNA (dsDNA) phages 34 . These molecules exert minimal toxicity toward host bacteria, allowing bacterial growth to continue, whereas the phage is neutralized, providing a selective advantage for bacteria in diverse environments 35 .

These small molecules are distinct from protein‐based systems because of their broad‐spectrum antiviral activity 34 . Targeting a fundamental step in the phage life cycle, DNA replication protects bacteria against a wide range of dsDNA phages. Moreover, these metabolites can diffuse within microbial communities, offering collective or population‐level protection 10 , 34 . Given the widespread production of such compounds by Streptomyces and other bacteria, chemical defense mechanisms likely play a crucial evolutionary role in shaping microbial community structures through robust and versatile antiphage activity.

Host modification systems

Restriction–modification (R–M) systems, found in approximately 83% of prokaryotes 36 , comprise a restriction endonuclease (REase) that recognizes and cleaves specific DNA sequences and a methyltransferase (MTase) that protects host DNA through methylation. The host DNA is methylated after replication to avoid cleavage, whereas unmethylated foreign DNA is degraded by REases. R–M systems are classified into four types, with type IV systems lacking MTase activity and targeting modified DNA 37 . Numerous viruses use 7‐deazaguanine modification in their genomes to avoid R–M recognition and cleavage 38 .

Bacteriophage exclusion (BREX) system, which is closely related to R–M systems, is found in 10% of microbial genomes and is divided into six subtypes 39 . BREX methylates host DNA but does not cleave foreign DNA, likely restricting phages through alternative mechanisms such as blocking viral replication or interfering with essential viral proteins 39 . Unlike traditional R–M systems, BREX uses non‐palindromic methylation patterns, suggesting a more complex mode of defense involving potential protein–protein interactions.

Defense island system associated with restriction–modification (DISARM) is another related system. It comprises five genes, methylates its own cytosine residues, and provides a broad‐spectrum viral defense 39 , 40 . Unlike canonical R–M systems, DISARM uses a multiprotein complex for DNA restriction 40 .

Phosphorothioation (PT)‐based R–M systems are a recently recognized class of R–M systems in which self‐modification is not methylation but a sulfur atom substituted for a non‐bridging oxygen in the phosphodiester backbone 41 . In the Dnd system, the DndABCDE cluster mediates PT modification of self‐DNA, whereas the DndFGH cluster restricts unmodified foreign DNA 42 . These modules function independently of one another. The DndFGH module alone encodes restriction, DNA binding, and ATP‐dependent helicase domains, establishing it as a standalone prokaryotic immune system 43 . Ssp system, which comprises the modification module SspABCD and the restriction module SspE, works with the Dnd system to provide broad‐spectrum viral resistance 42 . The Dnd system modifies dsDNA, whereas the Ssp system acts on single‐stranded DNA (ssDNA). Methylation of viral DNA does not hinder DndFGH‐mediated restriction, suggesting possible cooperation between classical R–M and PT systems in viral defense.

Argonaute systems

Prokaryotic Argonaute (pAgo) proteins, found in approximately 10% of bacteria and one‐third of archaea 36 , play a critical role in inhibiting the invasion of plasmids and viruses 44 . These Argonaute (Ago) proteins are homologous to their eukaryotic counterparts, but lack the accessory factors required for RNA interference (RNAi) 45 . pAgo systems acquire their guides from degraded fragments of invading DNA or RNA, which are usually generated by host nucleases such as RecBCD or AddAB 46 , 47 , 48 . Unlike CRISPR–Cas, pAgo lacks immune memory and relies on transient fragments for defense.

pAgos are categorized into long and short groups, each with distinct domain architectures and mechanisms 46 , 49 . Long pAgos possess a four‐domain structure (N‐PAZ‐MID‐PIWI). Unlike CRISPR–Cas, they cannot unwind and cleave dsDNA and use either ssDNA or RNA guides to target and cleave complementary foreign ssDNA or ssRNA, restricting phage or plasmid replication 46 , 49 . In contrast, short pAgos have a streamlined architecture (MID‐PIWI) and lack the catalytic activity required for cleavage 46 . However, short pAgos often possess APAZ domains, similar to the N domain of long pAgos, and are typically fused with other functional domains, such as SIR2 or Toll/interleukin‐1 receptor (TIR)‐like domains 46 . A representative example is the SPARTA system, in which a short pAgo forms a heterodimer with the TIR and APAZ domains 6 , 50 , 51 . This complex binds to the target ssDNA using small RNA guides, and oligomerizes to activate the NADase activity of the TIR domain, reducing NAD+ levels and inducing Abi activity 50 .

Reverse transcriptase (RT)

Prokaryotic retrons represent a branch of RT‐based defense systems composed of an RT, a noncoding RNA (ncRNA) that gives rise to multicopy ssDNA (msDNA), and a cognate effector protein 12 , 52 . Rather than executing defenses through a universal growth arrest mechanism, retrons form tripartite complexes in which msDNA directly interacts with the effector, and phage‐triggered perturbations activate effector functions to inhibit viral replication. For instance, in the well‐studied Ec86 retron, RT and msDNA assemble with a ribosyltransferase effector to form a supramolecular filament 53 , 54 . Phage‐encoded Dcm methylation of msDNA activates this filament, unleashing effector‐mediated NAD(P)+ hydrolysis and inhibiting infection 53 . By contrast, the Ec83 Retron–Septu system uses an “arrest‐and‐release” strategy: under normal conditions, msDNA sequesters the PtuAB nuclease complex in an autoinhibited state, whereas phage infection promotes msDNA degradation, releasing PtuAB to degrade ssDNA and restrict phage propagation 55 . Thus, retron defense relies on effector‐specific activation mechanisms, with msDNA acting as a molecular switch.

Defense‐associated reverse transcriptase (DRT) constitutes a distinct class of enzymes that offer robust protection against dsDNA phages. DRT systems typically synthesize cDNA from an ncRNA template during infection, producing dsDNA with an open reading frame (ORF) 56 , 57 . Translation of this ORF triggers growth arrest and halts the viral replication cycle. DRT systems are categorized into three classes based on their structure and function 58 . These systems illustrate how MGEs can defend against phages and drive genetic innovation 57 .

Prophage‐induced chromosomal islands (PICIs)

Phages can integrate their genes into host genomes as prophages, which play roles in HGT and phenotypic modulation (e.g., motility, antibiotic resistance, and metabolism) and serve as hotspots for defense systems 59 , 60 . PICIs limit phage proliferation by exploiting phage proteins for self‐packaging during infection 61 . PICI genomes (10–15 kb) assemble more efficiently than invading phage genomes but cannot completely inhibit replication. PICIs encode immune systems, such as MazF‐like (SMA) and higher eukaryotes and prokaryotes nucleotide binding transmembrane domain (HEPN‐TM), which provide broad defense. They also target MGEs by blocking HGT 62 . Phage‐induced chromosomal island‐like elements (PLEs), which are closely related to PICIs, are found in Vibrio cholerae and block phage replication and assembly by utilizing phage proteins.

Second‐messenger signaling systems

Cyclic oligonucleotide‐based antiphage signaling (CBASS) systems represent a major class of nucleotide‐based defense systems that can directly sense phage invasion and subsequently activate multiple effectors. CBASS is found in over 10% of prokaryotic genomes, with diverse effectors contributing to phage resistance 63 . CBASS sensors detect phage DNA or other molecular patterns and produce cyclic GMP–AMP (cGAMP) signaling molecules that activate various effectors 63 . These effectors include phospholipases, transmembrane proteins, nucleic acid‐degrading domains (HNH in Cap5 and REase in Cap4), and NAD+‐degrading domains (TIR‐SAVED). This self‐destructive cascade prevents the replication of phages.

Pyrimidine cyclase system for antiphage resistance (Pycsar) system uses pyrimidine cyclase PycC to produce 3′,5′‐cyclic cytidine monophosphate (cCMP) and 3′,5′‐cyclic uridine monophosphate (cUMP) as second messengers 64 . Upon phage detection, Pycsar enzymes synthesize cCMP and cUMP, which activate effectors that trigger cell death and prevent phage replication. Pycsar specifically uses cyclic pyrimidines to minimize interference with other cellular processes regulated by cyclic nucleotides such as cAMP.

Thoeris system also relies on nucleotide‐derived signaling but uses a distinct signaling molecule. Type I Thoeris systems, comprising ThsB and ThsA proteins, use ThsB to sense infection and generate 1″–3′ glycocyclic ADP‐ribose (gcADPR), which binds to the SLOG domain of ThsA and promotes filament assembly 19 . This structural change activates the SIR2 domain of ThsA, leading to rapid NAD+ depletion and halting of viral replication 19 , 65 . Filament formation ensures efficient phage resistance 66 . Type II Thoeris system expands this mechanism through an unconventional signaling molecule, histidine‐ADP‐ribose (His‐ADPR), generated by TIR domain‐containing proteins. His‐ADPR binds to the C‐terminal macrodomain of ThsA, inducing ThsA oligomerization and disrupting the bacterial cell membrane, ultimately triggering cell death and blocking phage infection 67 .

Kongming system uses a non‐canonical nucleotide, deoxyinosine triphosphate (dITP), as a second messenger, expanding the diversity of nucleotide‐based immunity 68 . KomA, phage deoxynucleotide monophosphate kinases (DNKs), and host nucleoside diphosphate kinases (NDKs) collaborate to synthesize dITP from phage‐derived dAMP, avoiding self‐toxicity through substrate specificity and metabolic regulation 68 . dITP binds to KomB, activating KomC to deplete NAD+ and trigger immunity 68 . Phages counteract this using Dmp enzymes (for dAMP depletion) and delaying DNK expression to block dITP synthesis 68 . This system introduces noncanonical nucleotides as immune signals, expands nucleotide‐based defense paradigms, and links them to eukaryotic mechanisms of action.

Toxin–antitoxin (TA) systems and Abi

TA systems exemplify the principle of prokaryotic antiviral defense, which couples molecular sensing with self‐elimination. They are broadly involved in stress responses, persistence, and biofilm formation and contribute to antiviral defense 69 . During phage infection, antitoxins are often destabilized or degraded, releasing toxins that cleave RNA or DNA, inhibit translation, or disrupt essential metabolic pathways, leading to growth arrest and/or cell death. Nucleases, particularly ribonucleases, are among the most prevalent toxins that cause rapid and efficient lethality 70 . TA modules are frequently embedded within defense islands and share extensive domain shuffling and functional overlap with other Abi‐associated systems 71 .

The distinction between Abi and TA is not clear‐cut. Abi typically involves distinct sensor–effector modules, in which sensors detect phage components and transmit activation signals to effectors that trigger abortive responses 72 . These responses include the inhibition of essential cellular processes (e.g., translation, transcription, and replication), degradation of key metabolites such as NAD+, and induction of membrane depolarization, ultimately leading to cell death and prevention of viral propagation 64 , 73 , 74 , 75 . For example, the RADAR system converts ATP into ITP, accumulating inosine mononucleotides that disrupt viral replication by disturbing nucleotide homeostasis and inducing metabolic imbalance 12 , 21 . The Zorya system uses proton channels to depolarize membranes and induces cell death or metabolic arrest to prevent phage replication 65 . Thus, recognizing Abi as a population‐level defense strategy rather than a standalone mechanistic class indicates that different systems use diverse sensors and execution modules while converging on a common defensive outcome.

Specific adaptive defense: CRISPR–Cas systems

Specific adaptive defense systems possess memory and adaptability, allowing rapid and specific responses based on the type and abundance of pathogens (Figure 3). Among prokaryotic immune mechanisms, only CRISPR–Cas systems show programmable adaptation, storing fragments of invading genetic material as molecular memories in CRISPR arrays.

Mechanism of CRISPR–Cas systems

CRISPR–Cas systems are found in approximately 50% of bacteria and 87% of archaea 16 . They are classified into two classes, over six types, and more than 30 subtypes 76 . The defense process involves three stages: adaptation, expression, and interference. During adaptation stage, fragments of invading DNA, called protospacers, are integrated into CRISPR arrays, forming heritable immune memory. Upon reinfection, CRISPR arrays are transcribed and processed into mature CRISPR RNAs (crRNAs), which guide Cas proteins to recognize and cleave target nucleic acids 77 . In Type II CRIPSR–Cas systems, trans‐activating CRISPR RNA (tracrRNA) assists in processing long precursor transcripts into mature crRNAs 78 .

During the adaptation stage, CRISPR memory is established via two pathways: naïve and primed. Both require the Cas1–Cas2 complex; however, primed adaptation also depends on a pre‐existing spacer that partially matches the invasive DNA, enhancing the acquisition efficiency 79 , 80 . In naïve adaptation, foreign DNA is processed by host double‐strand break repair enzymes (AddAB or RecBCD) 7 , 79 and captured as spacers by the Cas1–Cas2 complex 81 , 82 . Primed adaptation is directed by a pre‐existing spacer to related viruses; thus, it is more efficient and avoids self‐targeting. In some organisms, such as Haloarcula hispanica, the naïve pathway is inactivated to prevent self‐DNA acquisition 83 , whereas primed adaptation tolerates protospacer adjacent motif (PAM) mutations up to 23 variants 84 , ensuring effective non‐self‐discrimination while preventing viral evasion.

After adaptation, the expression and interference activate the immune system. During expression stage, precursor crRNAs are processed into mature crRNAs using Cas6 in most class 1 systems, RNase III in Type II systems, and Cas12 or Cas13 in some class 2 systems 85 . During interference guided by crRNAs, Cas protein complexes, such as the Cas complex for antiviral defense (Cascade) in class 1, or single effector proteins, such as Cas9, Cas12, or Cas13 in class 2, bind to and cleave foreign nucleic acids. Type III systems produce cyclic oligoadenylate (cOA) to activate different types of effectors, such as nucleases, proteases, or adenosine deaminases, leading to cell dormancy 86 , 87 . In addition, certain CRISPR–Cas systems exert antiviral activity via transcriptional inhibition of target genes (e.g., Cas12m) 88 .

CreTA safeguard systems

Although CRISPR–Cas systems are effective, they face viral countermeasures, most notably anti‐CRISPR (Acr) proteins that inhibit Cas effectors 89 . This has driven the evolution of CreTA, a TA–RNA pair associated with CRISPR loci that protects CRISPR–Cas integrity and regulates its activity 90 . The small RNA toxin CreT sequesters the rare arginine tRNAUCU, blocking protein synthesis and exerting a bacteriostatic effect. The RNA antitoxin CreA prevents CreT toxicity by repressing transcription via the Cascade complex. When viral Acr proteins disable the CRISPR–Cas systems, the protective function of CreTA is unleashed as a fail‐safe mechanism, triggering cell death 90 . In addition, CreR, a mini‐CRISPR regulatory RNA analogous to CreA, regulates CRISPR–Cas activity by sensing changes in crRNA abundance and modulating Cas protein expression to counteract Acr protein inhibition 91 .

Through these auxiliary modules, the CRISPR–Cas system co‐evolves with TA–RNA pairs to maintain immune and functional integrity. It can circumvent Acr inhibition by modifying the regulatory pathways, thus preserving immune function. These findings extend the current understanding of self‐regulation and antiviral resilience of CRISPR–Cas system and inspire new strategies for antibacterial applications, including targeting multidrug‐resistant pathogens (MDRs) 92 .

CRISPR–Cas ancestors

The evolutionary origins of CRISPR–Cas systems can be traced to two major ancestral lineages, IscB and TnpB nucleases, which are classified as Obligate Mobile Element Guided Activity (OMEGA) systems 93 . The localization and mobility of these transposon‐encoded nucleases likely influence their RNA guide specificity, suggesting multiple independent origins. Specifically, IscB proteins (originating from IS200/IS605 transposons), which are considered evolutionary precursors of Cas9, use ncRNA to guide dsDNA cleavage 93 . Similarly, TnpB proteins constitute the ancestor of Cas12 94 . By contrast, AbiF, a Type III TA system with a conserved ncRNA antitoxin, is a precursor of Cas13 95 . Unlike OMEGA systems with inherent RNA‐guided mechanisms, AbiF lacks RNA‐targeting specificity, moving to CRISPR–Cas13, a rare evolutionary leap. These findings provide distinct paths for CRISPR–Cas evolution: transposon‐derived OMEGA systems (Cas9/12) and TA‐derived systems (Cas13), highlighting how innate immune components can evolve into adaptive defenses during the host–pathogen arms race 96 .

Synergistic defense networks

The prokaryotic immune system achieves a multilayered defense by integrating innate and adaptive components. Ago systems degrade foreign nucleic acids but lack memory; however, their fragments serve as precursors for CRISPR spacers, linking nucleic acid‐guided degradation to adaptive memory 7 . Moreover, R–M systems enhance CRISPR spacer acquisition by generating DNA breaks, enhancing immune efficiency. Type I R–M systems promote Type VI CRISPR acquisition 97 , and in Streptococcus thermophilus, Type II CRISPR–Cas and Type II R–M systems synergize to strengthen the defense.

By integrating orthogonal defense modules and layered redundancy, prokaryotic defense networks achieve robustness against viral evolution while minimizing single‐point vulnerabilities. Retrons assist CRISPR adaptation by generating cDNA for new spacers 52 , 98 . The CRISPR Cascade complex inhibits the toxin CreT. When the CRISPR Cascade is inactivated, CreT sequesters the rare arginine tRNAUCU, halting cell growth 99 .

These individual adaptations scale up to population‐level resilience through optimized resource cooperation. Type I and Type III CRISPR–Cas systems are frequently colocalized with the pAgo cluster, suggesting their functional synergy 100 . Furthermore, Type I‐F CRISPR‐acquired spacers can be used by Type III‐B systems to enhance the robustness of defense and prevent viral escape 101 .

EVOLUTIONARY ADAPTATION AND ARMS RACE DYNAMICS

The evolution of prokaryotic defense systems exemplifies the continuous adaptation of life to viral challenges through molecular innovation and diversification. Selective pressure from phage predation has driven the emergence of intricate genetic architectures, such as repetitive sequences, modular proteins, and RNA‐guided machinery, which collectively enhance defense flexibility. These systems evolve under constant arms race dynamics, where each new bacterial strategy prompts viral countermeasures and refines the molecular precision on both sides. Over time, this process shapes prokaryotic genomic diversity and lays the foundation for the complex immune strategies observed in eukaryotes (Figure 4).

Figure 4.

Figure 4

Evolutionary adaptation and arms race dynamics. (A) Co‐evolution of defense and anti‐defense systems. Bacteria and phages engage in an ongoing evolutionary “cold war,” in which bacteria evolve various defense systems to combat phage attacks and phages develop countermeasures to evade these defenses. This arms race drives the co‐evolution of both species. HMC, hydroxymethylcytosine. (B) Horizontal gene transfer (HGT) and population‐level immunity. Bacteria acquire defense systems through HGT, which enhances their survival and increases adaptive costs. Defense genes often cluster in “defense islands,” reflecting their evolutionary adaptation via HGT. This process allows bacterial populations to share defense systems within the “pangenome.” (C) RNA–protein co‐evolution in defense systems. RNA‐guided mechanisms, which are integral to prokaryotic defense systems, highlight the co‐evolution of RNA and proteins. This interaction is evident in prokaryotic group II introns, eukaryotic R2 retrotransposons, and mammalian LINE‐1 retrotransposons, underscoring the transition from RNA to protein dominance in catalytic functions. (D) Prokaryotic origin of ancestral immunity in eukaryotes. The immune mechanisms of eukaryotes are closely linked to those of prokaryotes, with many eukaryotic systems likely inherited from prokaryotic ancestors.

Co‐evolution of defense systems and anti‐defense systems

The relationship between bacteria and phages resembles an evolutionary arms race, with constant attacks, resistance, and adaptation 2 . Bacteria have evolved diverse defense systems 9 , and phages continuously mutate to evade these systems (Figure 4A). This cycle of evolution and counter‐evolution maintains a dynamic balance in long‐term conflicts.

Building on this, prokaryotes have evolved remarkably diverse defense strategies, with most genomes (78%) encoding at least two defense systems 36 . These systems have undergone continuous evolution driven by natural selection, gene mutations, recombination, and HGT. The protective efficacy of a defense system is not absolute but varies with the genetic diversity of both the host and invading elements. For instance, prophages contribute to genomic complexity, whereas certain phage satellites can shift from parasitic to mutualistic states by competing with harmful phages 62 . Elucidating these complex interactions between competition and cooperation offers profound insights into the evolutionary dynamics of host–pathogen relationships.

In response to these host defenses, anti‐defense genes often cluster in viral genomes or MGEs. Phages frequently mutate and acquire anti‐defense proteins to evade the host defense systems. For example, phages have evolved diverse anti‐CRISPR (Acr) strategies with the discovery of Acr factors (Acrs), revealing the complexity of this molecular arms race. Early research focused on protein‐based Acrs 102 , 103 , whereas a recent study identified rAcrVIA1, an RNA‐based anti‐CRISPR factor (rAcr) that inhibits Cas13 via RNA structural mimicry rather than sequence homology 104 . Mechanistically, Acr proteins can be broadly classified into two categories: (i) target DNA binding inhibitors, which block recognition or crRNA function (e.g., AcrIIA4, AcrIIC3, AcrVA1, AcrVA5, and AcrIF1), and (ii) DNA cleavage inhibitors, which inhibit nuclease activity by binding to catalytic domains (e.g., AcrIIC1 and AcrIE1) 105 . Beyond Acrs, phages also encode sponge‐like proteins (e.g., Tad1, Tad2, Acb2, and Acb4) that sequester second messengers, such as cyclic oligonucleotides or related small signaling molecules, thus neutralizing CBASS, Thoeris, or Pycsar defenses without degrading those signals 95 .

Rearrangement of defense sensors and effectors counteracts the phage evasion. This ongoing adaptation and counter‐adaptation constantly drives co‐evolution. For example, T4 phage DNA with hydroxymethylcytosine (HMC) escapes recognition by cytosine‐based types I–III R–M systems. Escherichia coli counters a type IV R–M system (McrBC) that targets HMC‐containing DNA 106 . T4 phages then glycosylate their DNA, inhibiting McrBC activity. This prompts the evolution of the type IV system (GmrS–GmrD), which helps E. coli cleave glycosylated DNA 107 . This evolutionary arms race highlights the adaptability and evolutionary dynamics of both phages and bacteria.

As this ongoing co‐evolution continues, researchers have identified new defense systems, such as the phage anti‐restriction‐induced system (PARIS) 59 . The PARIS system, found in ~5.2% of prokaryotic genomes, encounters the T7 anti‐restriction protein Ocr, a phage‐encoded inhibitor of R–M and BREX systems 108 . By sensing Ocr and releasing AriB through the ArA–AriB module, PARIS triggers Abi, preventing phage propagation 59 . However, mutations in Ocr allow phages to escape PARIS and block EcoKI 59 . This arms race between prokaryotes and viruses demonstrates an intricate balance of adaptation between defenses and countermeasures, with the emergence of novel viral innovations, such as RNA‐based Acrs and sponge‐like proteins, further highlighting the dynamic co‐evolutionary landscape 109 , 110 . This interplay shapes evolution and reveals the complexity of microbial survival strategies, emphasizing the delicate equilibrium maintained at the evolutionary scale.

HGT and population‐level immunity

To survive, bacteria use HGT strategies to acquire various defense systems from MGEs (Figure 4B). MGEs, including phages, conjugative elements, satellites, and mobilizable elements, can move within or between genomes through unknown transfer mechanisms. These systems confer survival advantages but also impose adaptive costs, limiting the number of defense systems that bacteria can maintain, thus forming a co‐evolutionary network with their hosts 111 . Although individual strains may not possess all defense systems, HGT among bacterial populations enables them to indirectly access all defense systems within the “pangenome,” broadening immune protection 10 . Defense genes in bacteria and archaea are often clustered in “defense islands,” reflecting their evolutionary adaptation through the HGT of these systems.

HGT among bacteria, which facilitates the exchange of defense systems, suggests an evolutionary strategy in which collective immunity within bacterial populations takes precedence over individual defense capabilities. This pangenomic sharing highlights the evolutionary trade‐off between acquiring defense systems and managing associated metabolic costs.

RNA–protein co‐evolution in defense systems

RNA‐guided mechanisms, which are crucial for prokaryotic defense, likely represent ancient evolutionary traits that are foundational to the development of early life forms. These mechanisms are exemplified by two dominant nucleic acid–targeting systems: Ago and Cas proteins. Both systems use RNA‐mediated recognition to neutralize invasive genetic elements, underscoring their indispensable role in combating viral threats throughout evolution.

MGEs such as retrotransposons drive genomic diversification through targeted insertional mutagenesis and sequence expansion. Group II introns, originally identified as mobile retroelements in prokaryotes, are considered the evolutionary ancestors of more complex elements, such as eukaryotic non‐long terminal repeat (LTR) retrotransposons and spliceosome components 112 . These introns have demonstrated the capacity for host defense by disrupting other MGEs, suggesting their potential role in prokaryotic immunity 113 . A comparison of prokaryotic group II introns, eukaryotic R2 retrotransposons, and mammalian LINE‐1 retrotransposons revealed a gradual evolutionary shift in which RNA structural elements were progressively replaced by protein‐coding regions (Figure 4C) 114 . This shift moved from RNA‐based to protein‐based catalytic functions.

This evolutionary transition is further exemplified by CRISPR effectors, which show the co‐evolution of RNA and proteins. Larger Cas proteins correspond to smaller guide RNAs (gRNAs), indicating an inverse relationship 115 . This trend reflects the increasing importance of protein structure and enzymatic function. CRISPR effectors with larger Cas proteins and smaller gRNAs excel in DNA editing, whereas compact CRISPR–Cas systems are suitable for specific applications 116 .

These examples illustrate that RNA and proteins undergo complex interactions and co‐evolution during the evolution of prokaryotic defense systems. In the CRISPR–Cas systems, RNA's catalytic roles of RNA are increasingly dominated by proteins, highlighting their co‐evolution. This shift toward protein dominance boosts the efficacy of immune effectors against these genetic threats.

Prokaryotic origin of eukaryotic immune system

Evolutionary links exist between the defense systems of prokaryotes and those of eukaryotes. Certain structural domains and proteins originating from prokaryotic defense systems are evolutionarily conserved in eukaryotes and functionally contribute to the diverse stages of innate immunity signaling cascades (Figure 4D) 117 .

Prokaryotic Ago proteins are precursors of the RNA pathway in eukaryotes 118 . TnpB proteins in prokaryotes likely evolved into eukaryotic Fanzor (Fz) proteins 119 . Prokaryotic group II introns are precursors of eukaryotic nuclear splicing introns 120 , 121 . Similarly, bacterial CBASS systems are considered precursors of the cGAS–STING pathway in animal cells 63 . TIR domains are critical components of immune receptors in bacteria, plants, and animals 122 . cCMP and cUMP, first identified as antiphage second messengers in the bacterial Pycsar system, are co‐opted in mammals to regulate embryonic development (cCMP) and apoptosis (cUMP) 123 , underscoring their evolutionary conservation and functional diversification across domains. SAVED/CARF proteins act as second messenger receptors in both prokaryotes and eukaryotes 124 . This resemblance continues with nonspecific RNase cleavage activation by 2′‐5′‐oligoadenylate synthetase (OAS) in eukaryotes and Type III CRISPR–Cas systems in prokaryotes 63 . The bacterial Abi pathway is analogous to programmed cell death in eukaryotes, and NAD+ depletion is a self‐destructive mechanism in both prokaryotes and eukaryotes 125 . The pore‐forming functions of PycC pyrimidine cyclases and gasdermin proteins are similar in prokaryotes and eukaryotes 73 , 126 . The bacterial Bil system uses ubiquitin‐like protein E1 and E2 conjugating enzymes for antiphage defense 127 . During infection, this system attaches ubiquitin‐like proteins to the phage central tail fiber, disrupting its assembly and reducing its infectivity. This mechanism is analogous to that of the eukaryotic ISG15 system, in which ubiquitin‐like proteins inhibit viral replication. The shared ancestry of prokaryotic and eukaryotic immunity suggests the existence of complex immune systems in higher organisms, which stem from bacterial‐defense strategies. This link underscores the fundamental role of prokaryotic systems in the evolution of the eukaryotic immune system.

CONCLUDING REMARKS

Prokaryotic antiviral defense systems show remarkable mechanistic and evolutionary diversity, shaped by long‐standing phage arms races. Despite their variety, numerous defenses rely on conserved components, such as nucleases, signaling proteins, or Abi effectors, which are recurrently repurposed across lineages, forming a modular and interconnected immune network rather than a set of isolated systems 65 , 128 . Comparative studies have uncovered unexpected mechanistic parallels, such as cyclic nucleotide signaling shared by CBASS and Type III CRISPR–Cas, whereas retrons use TA activation strategies 98 , 129 .

Besides their biological importance, these systems have substantial translational relevance. CRISPR nucleases have revolutionized genome editing 78 , 130 , whereas retrons, OMEGA nucleases, and cyclic oligonucleotide‐based effectors further enrich the molecular toolkit 93 , 131 , 132 . Recently, the concept of “append editing” was introduced, in which the bacterial antiphage toxin DarT2 is harnessed to append ADP‐ribosyl groups to DNA, enabling templated repair in bacteria and base mutagenesis in eukaryotes. By fusing attenuated DarT2 to Cas9 nickase, site‐specific ADP‐ribosylation of thymine residues can be programmatically induced, offering editing outcomes beyond the reach of current base editors 133 . Moreover, the broad repertoire of defense‐associated toxins and signaling enzymes provides promising avenues for developing antimicrobials against MDRs based on the rational exploitation of phage–bacterial interactions 134 .

New discoveries will increasingly rely on AI‐assisted genome mining, terascale clustering, and integrative multi‐omics 135 . Approaches such as Evo genome‐scale modeling and deep learning‐guided inference of defense architectures 136 , 137 combined with high‐resolution structural biology 138 are expected to reveal cryptic or composite systems and illuminate their evolutionary logic. Ultimately, viewing prokaryotic defense through modular and translational perspectives establishes it not only as a historical record of host–virus conflicts but also as a rich source of next‐generation biotechnological tools and anti‐infective strategies 139 , 140 , 141 .

ACKNOWLEDGMENTS

This work was supported by the grants from the National Natural Science Foundation of China (32230061 to H.X.) and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB0810000 to H.X.).

REFERENCES

  • 1. Breitbart M, Rohwer F. Here a virus, there a virus, everywhere the same virus? Trends Microbiol. 2005;13:278–284. [DOI] [PubMed] [Google Scholar]
  • 2. Hampton HG, Watson BNJ, Fineran PC. The arms race between bacteria and their phage foes. Nature. 2020;577:327–336. [DOI] [PubMed] [Google Scholar]
  • 3. Chaudhury P, Quax TEF, Albers SV. Versatile cell surface structures of archaea. Mol Microbiol. 2018;107:298–311. [DOI] [PubMed] [Google Scholar]
  • 4. Hansen MF, Svenningsen SL, Røder HL, Middelboe M, Burmølle M. Big impact of the tiny: bacteriophage–bacteria interactions in biofilms. Trends Microbiol. 2019;27:739–752. [DOI] [PubMed] [Google Scholar]
  • 5. Loeff L, Walter A, Rosalen GT, Jinek M. DNA end sensing and cleavage by the Shedu anti‐phage defense system. Cell. 2025;188:721–733. [DOI] [PubMed] [Google Scholar]
  • 6. Guo L, Huang P, Li Z, Shin Y‐C, Yan P, Lu M, et al. Auto‐inhibition and activation of a short Argonaute‐associated TIR‐APAZ defense system. Nat Chem Biol. 2024;20:512–520. [DOI] [PubMed] [Google Scholar]
  • 7. Modell JW, Jiang W, Marraffini LA. CRISPR–Cas systems exploit viral DNA injection to establish and maintain adaptive immunity. Nature. 2017;544:101–104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Lopatina A, Tal N, Sorek R. Abortive infection: bacterial suicide as an antiviral immune strategy. Ann Rev Virol. 2020;7:371–384. [DOI] [PubMed] [Google Scholar]
  • 9. Rostøl JT, Marraffini L. (Ph)ighting phages: how bacteria resist their parasites. Cell Host Microbe. 2019;25:184–194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Bernheim A, Sorek R. The pan‐immune system of bacteria: antiviral defence as a community resource. Nat Rev Microbiol. 2020;18:113–119. [DOI] [PubMed] [Google Scholar]
  • 11. Nomburg J, Doherty EE, Price N, Bellieny‐Rabelo D, Zhu YK, Doudna JA. Birth of protein folds and functions in the virome. Nature. 2024;633:710–717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Gao L, Altae‐Tran H, Böhning F, Makarova KS, Segel M, Schmid‐Burgk JL, et al. Diverse enzymatic activities mediate antiviral immunity in prokaryotes. Science. 2020;369:1077–1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Altae‐Tran H, Kannan S, Suberski AJ, Mears KS, Demircioglu FE, Moeller L, et al. Uncovering the functional diversity of rare CRISPR‐Cas systems with deep terascale clustering. Science. 2023;382:eadi1910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. García‐Bayona L, Comstock LE. Bacterial antagonism in host‐associated microbial communities. Science. 2018;361:eaat2456. [DOI] [PubMed] [Google Scholar]
  • 15. Wang JY, Doudna JA. CRISPR technology: a decade of genome editing is only the beginning. Science. 2023;379:eadd8643. [DOI] [PubMed] [Google Scholar]
  • 16. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, et al. An updated evolutionary classification of CRISPR–Cas systems. Nat Rev Microbiol. 2015;13:722–736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Li Y, Shen Z, Zhang M, Yang X‐Y, Cleary SP, Xie J, et al. PtuA and PtuB assemble into an inflammasome‐like oligomer for anti‐phage defense. Nat Struct Mol Biol. 2024;31:413–423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Cheng R, Huang F, Wu H, Lu X, Yan Y, Yu B, et al. A nucleotide‐sensing endonuclease from the Gabija bacterial defense system. Nucleic Acids Res. 2021;49:5216–5229. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Tamulaitiene G, Sabonis D, Sasnauskas G, Ruksenaite A, Silanskas A, Avraham C, et al. Activation of Thoeris antiviral system via SIR2 effector filament assembly. Nature. 2024;627:431–436. [DOI] [PubMed] [Google Scholar]
  • 20. Leavitt A, Yirmiya E, Amitai G, Lu A, Garb J, Herbst E, et al. Viruses inhibit TIR gcADPR signalling to overcome bacterial defence. Nature. 2022;611:326–331. [DOI] [PubMed] [Google Scholar]
  • 21. Duncan‐Lowey B, Tal N, Johnson AG, Rawson S, Mayer ML, Doron S, et al. Cryo‐EM structure of the RADAR supramolecular anti‐phage defense complex. Cell. 2023;186:987–998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. An Q, Wang Y, Tian Z, Han J, Li J, Liao F, et al. Molecular and structural basis of an ATPase‐nuclease dual‐enzyme anti‐phage defense complex. Cell Res. 2024;34:545–555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Tang D, Chen Y, Chen H, Jia T, Chen Q, Yu Y. Multiple enzymatic activities of a Sir2‐HerA system cooperate for anti‐phage defense. Mol Cell. 2023;83:4600–4613.e6. [DOI] [PubMed] [Google Scholar]
  • 24. Tuck OT, Adler BA, Armbruster EG, Lahiri A, Hu JJ, Zhou J, et al. Genome integrity sensing by the broad‐spectrum Hachiman antiphage defense complex. Cell. 2024;187:6914–6928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Stokar‐Avihail A, Fedorenko T, Hör J, Garb J, Leavitt A, Millman A, et al. Discovery of phage determinants that confer sensitivity to bacterial immune systems. Cell. 2023;186:1863–1876.e16. [DOI] [PubMed] [Google Scholar]
  • 26. Harvey H, Bondy‐Denomy J, Marquis H, Sztanko KM, Davidson AR, Burrows LL. Pseudomonas aeruginosa defends against phages through type IV pilus glycosylation. Nat Microbiol. 2017;3:47–52. [DOI] [PubMed] [Google Scholar]
  • 27. Chung I‐Y, Jang H‐J, Bae H‐W, Cho Y‐H. A phage protein that inhibits the bacterial ATPase required for type IV pilus assembly. Proc Natl Acad Sci USA. 2014;111:11503–11508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Shen C, Chang S, Luo Q, Chan KC, Zhang Z, Luo B, et al. Structural basis of BAM‐mediated outer membrane β‐barrel protein assembly. Nature. 2023;617:185–193. [DOI] [PubMed] [Google Scholar]
  • 29. Bołoz A, Lannoy V, Olszak T, Drulis‐Kawa Z, Augustyniak D. Interplay between bacterial extracellular vesicles and phages: receptors, mechanisms, and implications. Viruses. 2025;17:1180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Albers S‐V, Meyer BH. The archaeal cell envelope. Nat Rev Microbiol. 2011;9:414–426. [DOI] [PubMed] [Google Scholar]
  • 31. Klingl A. S‐layer and cytoplasmic membrane—exceptions from the typical archaeal cell wall with a focus on double membranes. Front Microbiol. 2014;5:624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Quemin ERJ, Quax TEF. Archaeal viruses at the cell envelope: entry and egress. Front Microbiol. 2015;6:552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Lucas X, Senger C, Erxleben A, Gruning BA, Doring K, Mosch J, et al. StreptomeDB: a resource for natural compounds isolated from Streptomyces species. Nucleic Acids Res. 2013;41:D1130–D1136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Hardy A, Kever L, Frunzke J. Antiphage small molecules produced by bacteria—beyond protein‐mediated defenses. Trends Microbiol. 2023;31:92–106. [DOI] [PubMed] [Google Scholar]
  • 35. Kronheim S, Daniel‐Ivad M, Duan Z, Hwang S, Wong AI, Mantel I, et al. A chemical defence against phage infection. Nature. 2018;564:283–286. [DOI] [PubMed] [Google Scholar]
  • 36. Tesson F, Hervé A, Mordret E, Touchon M, d'Humières C, Cury J, et al. Systematic and quantitative view of the antiviral arsenal of prokaryotes. Nat Commun. 2022;13:2561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Vasu K, Nagaraja V. Diverse functions of restriction‐modification systems in addition to cellular defense. Microbiol Mol Biol Rev. 2013;77:53–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Kot W, Olsen NS, Nielsen TK, Hutinet G, De crécy‐Lagard V, Cui L, et al. Detection of preQ0 deazaguanine modifications in bacteriophage CAjan DNA using nanopore sequencing reveals same hypermodification at two distinct DNA motifs. Nucleic Acids Res. 2020;48:10383–10396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Goldfarb T, Sberro H, Weinstock E, Cohen O, Doron S, Charpak‐Amikam Y, et al. brex is a novel phage resistance system widespread in microbial genomes. EMBO J. 2015;34:169–183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Ofir G, Melamed S, Sberro H, Mukamel Z, Silverman S, Yaakov G, et al. DISARM is a widespread bacterial defence system with broad anti‐phage activities. Nat Microbiol. 2017;3:90–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Wang L, Jiang S, Deng Z, Dedon PC, Chen S. DNA phosphorothioate modification—a new multi‐functional epigenetic system in bacteria. FEMS Microbiol Rev. 2019;43:109–122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Jiang S, Chen K, Wang Y, Zhang Y, Tang Y, Huang W, et al. A DNA phosphorothioation‐based Dnd defense system provides resistance against various phages and is compatible with the Ssp defense system. mBio. 2023;14:e0093323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Rakesh S, Aravind L, Krishnan A. Reappraisal of the DNA phosphorothioate modification machinery: uncovering neglected functional modalities and identification of new counter‐invader defense systems. Nucleic Acids Res. 2024;52:1005–1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Swarts DC, Jore MM, Westra ER, Zhu Y, Janssen JH, Snijders AP, et al. DNA‐guided DNA interference by a prokaryotic Argonaute. Nature. 2014;507:258–261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Zeng Z, Chen Y, Pinilla‐Redondo R, Shah SA, Zhao F, Wang C, et al. A short prokaryotic Argonaute activates membrane effector to confer antiviral defense. Cell Host Microbe. 2022;30:930–943.e6. [DOI] [PubMed] [Google Scholar]
  • 46. Swarts DC, Makarova K, Wang Y, Nakanishi K, Ketting RF, Koonin EV, et al. The evolutionary journey of Argonaute proteins. Nat Struct Mol Biol. 2014;21:743–753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. El Karoui M, Biaudet V, Schbath S, Gruss A. Characteristics of Chi distribution on different bacterial genomes. Res Microbiol. 1999;150:579–587. [DOI] [PubMed] [Google Scholar]
  • 48. Portnoy V, Lin SHS, Li KH, Burlingame A, Hu Z‐H, Li H, et al. saRNA‐guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 2016;26:320–335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Ryazansky S, Kulbachinskiy A, Aravin AA. The expanded universe of prokaryotic Argonaute proteins. mBio. 2018;9:e01935‐18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Shen Z, Yang X‐Y, Xia S, Huang W, Taylor DJ, Nakanishi K, et al. Oligomerization‐mediated activation of a short prokaryotic Argonaute. Nature. 2023;621:154–161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Koopal B, Potocnik A, Mutte SK, Aparicio‐Maldonado C, Lindhoud S, Vervoort JJM, et al. Short prokaryotic Argonaute systems trigger cell death upon detection of invading DNA. Cell. 2022;185:1471–1486.e19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Millman A, Bernheim A, Stokar‐Avihail A, Fedorenko T, Voichek M, Leavitt A, et al. Bacterial retrons function in anti‐phage defense. Cell. 2020;183:1551–1561.e12. [DOI] [PubMed] [Google Scholar]
  • 53. Wang Y, Wang C, Guan Z, Cao J, Xu J, Wang S, et al. DNA methylation activates retron Ec86 filaments for antiphage defense. Cell Rep. 2024;43:114857. [DOI] [PubMed] [Google Scholar]
  • 54. Wang Y, Guan Z, Wang C, Nie Y, Chen Y, Qian Z, et al. Cryo‐EM structures of Escherichia coli Ec86 retron complexes reveal architecture and defence mechanism. Nat Microbiol. 2022;7:1480–1489. [DOI] [PubMed] [Google Scholar]
  • 55. Wang C, Rish AD, Armbruster EG, Xie J, Loveland AB, Shen Z, et al. Disassembly activates retron‐septu for antiphage defense. Science. 2025;389:eadv3344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Wilkinson ME, Li D, Gao A, Macrae RK, Zhang F. Phage‐triggered reverse transcription assembles a toxic repetitive gene from a noncoding RNA. Science. 2024;386:eadq3977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Tang S, Conte V, Zhang DJ, Žedaveinytė R, Lampe GD, Wiegand T, et al. De novo gene synthesis by an antiviral reverse transcriptase. Science. 2024;386:eadq0876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Mestre MR, Gao LA, Shah SA, López‐Beltrán A, González‐Delgado A, Martínez‐Abarca F, et al. UG/abi: a highly diverse family of prokaryotic reverse transcriptases associated with defense functions. Nucleic Acids Res. 2022;50: 6084–6101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Rousset F, Depardieu F, Miele S, Dowding J, Laval A‐L, Lieberman E, et al. Phages and their satellites encode hotspots of antiviral systems. Cell Host Microbe. 2022;30:740–753.e5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Vassallo CN, Doering CR, Littlehale ML, Teodoro GIC, Laub MT. A functional selection reveals previously undetected anti‐phage defence systems in the E. coli pangenome. Nat Microbiol. 2022;7:1568–1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Fillol‐Salom A, Miguel‐Romero L, Marina A, Chen J, Penadés JR. Beyond the CRISPR‐Cas safeguard: PICI‐encoded innate immune systems protect bacteria from bacteriophage predation. Curr Opin Microbiol. 2020;56:52–58. [DOI] [PubMed] [Google Scholar]
  • 62. Fillol‐Salom A, Rostøl JT, Ojiogu AD, Chen J, Douce G, Humphrey S, et al. Bacteriophages benefit from mobilizing pathogenicity islands encoding immune systems against competitors. Cell. 2022;185:3248–3262.e20. [DOI] [PubMed] [Google Scholar]
  • 63. Cohen D, Melamed S, Millman A, Shulman G, Oppenheimer‐Shaanan Y, Kacen A, et al. Cyclic GMP–AMP signalling protects bacteria against viral infection. Nature. 2019;574:691–695. [DOI] [PubMed] [Google Scholar]
  • 64. Tal N, Morehouse BR, Millman A, Stokar‐Avihail A, Avraham C, Fedorenko T, et al. Cyclic CMP and cyclic UMP mediate bacterial immunity against phages. Cell. 2021;184:5728–5739.e16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Doron S, Melamed S, Ofir G, Leavitt A, Lopatina A, Keren M, et al. Systematic discovery of antiphage defense systems in the microbial pangenome. Science. 2018;359:eaar4120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Ka D, Oh H, Park E, Kim J‐H, Bae E. Structural and functional evidence of bacterial antiphage protection by thoeris defense system via NAD+ degradation. Nat Commun. 2020;11:2816. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Sabonis D, Avraham C, Chang RB, Lu A, Herbst E, Silanskas A, et al. TIR domains produce histidine‐ADPR as an immune signal in bacteria. Nature. 2025;642:467–473. [DOI] [PubMed] [Google Scholar]
  • 68. Zeng Z, Hu Z, Zhao R, Rao J, Mestre MR, Liu Y, et al. Base‐modified nucleotides mediate immune signaling in bacteria. Science. 2025;388:eads6055. [DOI] [PubMed] [Google Scholar]
  • 69. Page R, Peti W. Toxin‐antitoxin systems in bacterial growth arrest and persistence. Nat Chem Biol. 2016;12:208–214. [DOI] [PubMed] [Google Scholar]
  • 70. Garcia‐Rodriguez G, Charlier D, Wilmaerts D, Michiels J, Loris R. Alternative dimerization is required for activity and inhibition of the HEPN ribonuclease RnlA. Nucleic Acids Res. 2021;49:7164–7178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Makarova KS, Wolf YI, Koonin EV. Comparative genomics of defense systems in archaea and bacteria. Nucleic Acids Res. 2013;41:4360–4377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Rousset F, Sorek R. The evolutionary success of regulated cell death in bacterial immunity. Curr Opin Microbiol. 2023;74:102312. [DOI] [PubMed] [Google Scholar]
  • 73. Johnson AG, Wein T, Mayer ML, Duncan‐Lowey B, Yirmiya E, Oppenheimer‐Shaanan Y, et al. Bacterial gasdermins reveal an ancient mechanism of cell death. Science. 2022;375:221–225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Zhang T, Tamman H, Coppieters't Wallant K, Kurata T, LeRoux M, Srikant S, et al. Direct activation of a bacterial innate immune system by a viral capsid protein. Nature. 2022;612:132–140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Gao LA, Wilkinson ME, Strecker J, Makarova KS, Macrae RK, Koonin EV, et al. Prokaryotic innate immunity through pattern recognition of conserved viral proteins. Science. 2022;377:eabm4096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Yang J, Li X, He Q, Wang X, Tang J, Wang T, et al. Structural basis for the activity of the type VII CRISPR–Cas system. Nature. 2024;633:465–472. [DOI] [PubMed] [Google Scholar]
  • 77. Hille F, Richter H, Wong SP, Bratovič M, Ressel S, Charpentier E. The biology of CRISPR‐Cas: backward and forward. Cell. 2018;172:1239–1259. [DOI] [PubMed] [Google Scholar]
  • 78. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual‐RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816–821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. Jackson SA, McKenzie RE, Fagerlund RD, Kieper SN, Fineran PC, Brouns SJJ. CRISPR‐Cas: adapting to change. Science. 2017;356:eaal5056. [DOI] [PubMed] [Google Scholar]
  • 80. Li M, Gong L, Zhao D, Zhou J, Xiang H. The spacer size of I‐B CRISPR is modulated by the terminal sequence of the protospacer. Nucleic Acids Res. 2017;45:4642–4654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Nuñez JK, Lee ASY, Engelman A, Doudna JA. Integrase‐mediated spacer acquisition during CRISPR–Cas adaptive immunity. Nature. 2015;519:193–198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Levy A, Goren MG, Yosef I, Auster O, Manor M, Amitai G, et al. CRISPR adaptation biases explain preference for acquisition of foreign DNA. Nature. 2015;520:505–510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Li M, Wang R, Zhao D, Xiang H. Adaptation of the Haloarcula hispanica CRISPR‐Cas system to a purified virus strictly requires a priming process. Nucleic Acids Res. 2014;42:2483–2492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84. Li M, Wang R, Xiang H. Haloarcula hispanica CRISPR authenticates PAM of a target sequence to prime discriminative adaptation. Nucleic Acids Res. 2014;42:7226–7235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85. Makarova KS, Wolf YI, Iranzo J, Shmakov SA, Alkhnbashi OS, Brouns SJJ, et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat Rev Microbiol. 2020;18:67–83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Athukoralage JS, McMahon SA, Zhang C, Grüschow S, Graham S, Krupovic M, et al. An anti‐CRISPR viral ring nuclease subverts type III CRISPR immunity. Nature. 2020;577:572–575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Niewoehner O, Garcia‐Doval C, Rostøl JT, Berk C, Schwede F, Bigler L, et al. Type III CRISPR–Cas systems produce cyclic oligoadenylate second messengers. Nature. 2017;548:543–548. [DOI] [PubMed] [Google Scholar]
  • 88. Wu WY, Mohanraju P, Liao C, Adiego‐Pérez B, Creutzburg SCA, Makarova KS, et al. The miniature CRISPR‐Cas12m effector binds DNA to block transcription. Mol Cell. 2022;82:4487–4502.e7. [DOI] [PubMed] [Google Scholar]
  • 89. Borges AL, Davidson AR, Bondy‐Denomy J. The discovery, mechanisms, and evolutionary impact of anti‐CRISPRs. Ann Rev Virol. 2017;4:37–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Li M, Gong L, Cheng F, Yu H, Zhao D, Wang R, et al. Toxin‐antitoxin RNA pairs safeguard CRISPR‐Cas systems. Science. 2021;372:eabe5601. [DOI] [PubMed] [Google Scholar]
  • 91. Liu C, Wang R, Li J, Cheng F, Shu X, Zhao H, et al. Widespread RNA‐based cas regulation monitors crRNA abundance and anti‐CRISPR proteins. Cell Host Microbe. 2023;31:1481–1493. [DOI] [PubMed] [Google Scholar]
  • 92. Wang R, Shu X, Zhao H, Xue Q, Liu C, Wu A, et al. Associate toxin‐antitoxin with CRISPR‐Cas to kill multidrug‐resistant pathogens. Nat Commun. 2023;14:2078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Altae‐Tran H, Kannan S, Demircioglu FE, Oshiro R, Nety SP, McKay LJ, et al. The widespread IS200/IS605 transposon family encodes diverse programmable RNA‐guided endonucleases. Science. 2021;374:57–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Karvelis T, Druteika G, Bigelyte G, Budre K, Zedaveinyte R, Silanskas A, et al. Transposon‐associated TnpB is a programmable RNA‐guided DNA endonuclease. Nature. 2021;599:692–696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Zilberzwige‐Tal S, Altae‐Tran H, Kannan S, Wilkinson ME, Vo SC‐D‐T, Strebinger D, et al. Reprogrammable RNA‐targeting CRISPR systems evolved from RNA toxin‐antitoxins. Cell. 2025;188:1925–1940.e20. [DOI] [PubMed] [Google Scholar]
  • 96. Hirano S, Kappel K, Altae‐Tran H, Faure G, Wilkinson ME, Kannan S, et al. Structure of the OMEGA nickase IsrB in complex with ωRNA and target DNA. Nature. 2022;610:575–581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Weissman J, Stoltzfus A, Westra ER, Johnson PLF. Avoidance of self during CRISPR immunization. Trends Microbiol. 2020;28:543–553. [DOI] [PubMed] [Google Scholar]
  • 98. Bobonis J, Mitosch K, Mateus A, Karcher N, Kritikos G, Selkrig J, et al. Bacterial retrons encode phage‐defending tripartite toxin–antitoxin systems. Nature. 2022;609:144–150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Cheng F, Wang R, Yu H, Liu C, Yang J, Xiang H, et al. Divergent degeneration of creA antitoxin genes from minimal CRISPRs and the convergent strategy of tRNA‐sequestering CreT toxins. Nucleic Acids Res. 2021;49:10677–10688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Kuzmenko A, Oguienko A, Esyunina D, Yudin D, Petrova M, Kudinova A, et al. DNA targeting and interference by a bacterial Argonaute nuclease. Nature. 2020;587:632–637. [DOI] [PubMed] [Google Scholar]
  • 101. Silas S, Lucas‐Elio P, Jackson SA, Aroca‐Crevillén A, Hansen LL, Fineran PC, et al. Type III CRISPR‐Cas systems can provide redundancy to counteract viral escape from type I systems. eLife. 2017;6:e27601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102. Birkholz N, Kamata K, Feussner M, Wilkinson ME, Cuba Samaniego C, Migur A, et al. Phage anti‐CRISPR control by an RNA‐ and DNA‐binding helix–turn–helix protein. Nature. 2024;631:670–677. [DOI] [PubMed] [Google Scholar]
  • 103. Trost CN, Yang J, Garcia B, Hidalgo‐Reyes Y, Fung BCM, Wang J, et al. An anti‐CRISPR that pulls apart a CRISPR–cas complex. Nature. 2024;632:375–382. [DOI] [PubMed] [Google Scholar]
  • 104. Hayes VM, Zhang J‐T, Katz MA, Li Y, Kocsis B, Brinkley DM, et al. RNA‐mediated CRISPR‐Cas13 inhibition through crRNA structural mimicry. Science. 2025;388:387–391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Marino ND, Pinilla‐Redondo R, Csörgő B, Bondy‐Denomy J. Anti‐CRISPR protein applications: natural brakes for CRISPR‐cas technologies. Nat Methods. 2020;17:471–479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Raleigh EA, Wilson G. Escherichia coli K‐12 restricts DNA containing 5‐methylcytosine. Proc Natl Acad Sci USA. 1986;83:9070–9074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Bair CL, Black LW. A type IV modification dependent restriction nuclease that targets glucosylated hydroxymethyl cytosine modified DNAs. J Mol Biol. 2007;366:768–778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Isaev A, Drobiazko A, Sierro N, Gordeeva J, Yosef I, Qimron U, et al. Phage T7 DNA mimic protein Ocr is a potent inhibitor of BREX defence. Nucleic Acids Res. 2020;48:5397–5406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Wang L, Zheng R, Zhang L. Sequestering survival: sponge‐like proteins in phage evasion of bacterial immune defenses. Front Immunol. 2025;16:1545308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110. Richmond‐Buccola D, Kranzusch PJ. Viral sponges sequester nucleotide signals to inactivate immunity. Trends Microbiol. 2023;31:552–553. [DOI] [PubMed] [Google Scholar]
  • 111. Koonin EV, Makarova KS, Wolf YI, Krupovic M. Evolutionary entanglement of mobile genetic elements and host defence systems: guns for hire. Nat Rev Genet. 2020;21:119–131. [DOI] [PubMed] [Google Scholar]
  • 112. González‐Delgado A, Mestre MR, Martínez‐Abarca F, Toro N. Prokaryotic reverse transcriptases: from retroelements to specialized defense systems. FEMS Microbiol Rev. 2021;45:fuab025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113. Qu G, Piazza CL, Smith D, Belfort M. Group II intron inhibits conjugative relaxase expression in bacteria by mRNA targeting. eLife. 2018;7:e34268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Deng P, Tan S‐Q, Yang Q‐Y, Fu L, Wu Y, Zhu H‐Z, et al. Structural RNA components supervise the sequential DNA cleavage in R2 retrotransposon. Cell. 2023;186:2865–2879. [DOI] [PubMed] [Google Scholar]
  • 115. Sun A, Li C‐P, Chen Z, Zhang S, Li D‐Y, Yang Y, et al. The compact Casπ (Cas12l) “bracelet” provides a unique structural platform for DNA manipulation. Cell Res. 2023;33:229–244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Guo J, Gong L, Yu H, Li M, An Q, Liu Z, et al. Engineered minimal type I CRISPR‐Cas system for transcriptional activation and base editing in human cells. Nat Commun. 2024;15:7277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117. Bernheim A, Cury J, Poirier EZ. The immune modules conserved across the tree of life: towards a definition of ancestral immunity. PLoS Biol. 2024;22:e3002717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118. Koonin EV. Evolution of RNA‐ and DNA‐guided antivirus defense systems in prokaryotes and eukaryotes: common ancestry vs convergence. Biol Direct. 2017;12:5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Saito M, Xu P, Faure G, Maguire S, Kannan S, Altae‐Tran H, et al. Fanzor is a eukaryotic programmable RNA‐guided endonuclease. Nature. 2023;620:660–668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120. Wells JN, Feschotte C. A field guide to eukaryotic transposable elements. Annu Rev Genet. 2020;54:539–561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121. Gorbunova V, Seluanov A, Mita P, McKerrow W, Fenyö D, Boeke JD, et al. The role of retrotransposable elements in ageing and age‐associated diseases. Nature. 2021;596:43–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Horsefield S, Burdett H, Zhang X, Manik MK, Shi Y, Chen J, et al. NAD+ cleavage activity by animal and plant TIR domains in cell death pathways. Science. 2019;365:793–799. [DOI] [PubMed] [Google Scholar]
  • 123. Seifert R. cCMP and cUMP across the tree of life: from cCMP and cUMP generators to cCMP‐ and cUMP‐regulated cell functions. Handb Exp Pharmacol. 2017;238:3–23. [DOI] [PubMed] [Google Scholar]
  • 124. Lowey B, Whiteley AT, Keszei AFA, Morehouse BR, Mathews IT, Antine SP, et al. CBASS immunity uses CARF‐related effectors to sense 3′–5′‐ and 2′–5′‐Linked cyclic oligonucleotide signals and protect bacteria from phage infection. Cell. 2020;182:38–49.e17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125. Pajuelo D, Gonzalez‐Juarbe N, Tak U, Sun J, Orihuela CJ, Niederweis M. NAD+ depletion triggers macrophage necroptosis, a cell death pathway exploited by Mycobacterium tuberculosis . Cell Rep. 2018;24:429–440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Wang C, Shivcharan S, Tian T, Wright S, Ma D, Chang J, et al. Structural basis for GSDMB pore formation and its targeting by IpaH7.8. Nature. 2023;616:590–597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Hör J, Wolf SG, Sorek R. Bacteria conjugate ubiquitin‐like proteins to interfere with phage assembly. Nature. 2024;631:850–856. [DOI] [PubMed] [Google Scholar]
  • 128. Payne LJ, Todeschini TC, Wu Y, Perry BJ, Ronson CW, Fineran PC, et al. Identification and classification of antiviral defence systems in bacteria and archaea with PADLOC reveals new system types. Nucleic Acids Res. 2021;49:10868–10878. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129. Millman A, Melamed S, Amitai G, Sorek R. Diversity and classification of cyclic‐oligonucleotide‐based anti‐phage signalling systems. Nat Microbiol. 2020;5:1608–1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130. Pacesa M, Pelea O, Jinek M. Past, present, and future of CRISPR genome editing technologies. Cell. 2024;187:1076–1100. [DOI] [PubMed] [Google Scholar]
  • 131. Simon AJ, Ellington AD, Finkelstein IJ. Retrons and their applications in genome engineering. Nucleic Acids Res. 2019;47:11007–11019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Lau RK, Ye Q, Birkholz EA, Berg KR, Patel L, Mathews IT, et al. Structure and mechanism of a cyclic trinucleotide‐activated bacterial endonuclease mediating bacteriophage immunity. Mol Cell. 2020;77:723–733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133. Gupta D, Patinios C, Bassett HV, Kibe A, Collins SP, Kamm C, et al. Targeted DNA ADP‐ribosylation triggers templated repair in bacteria and base mutagenesis in eukaryotes. Nat Biotechnol. 2025; 10.1038/s41587-025-02802-w [DOI] [PubMed] [Google Scholar]
  • 134. Mangalea MR, Duerkop BA. Fitness trade‐offs resulting from bacteriophage resistance potentiate synergistic antibacterial strategies. Infect Immun. 2020;88:e00926‐19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135. Wang Z, Wang Y, Gao H, Dai J, Tang N, Wang Y, et al. AI‐driven discovery of host thioredoxin as a CRISPR enhancer of phage‐encoded miniature Cas12 hacker nuclease. bioRxiv. 2025; 10.1101/2025.01.20.633832 [DOI] [Google Scholar]
  • 136. Steinegger M, Söding J. Clustering huge protein sequence sets in linear time. Nat Commun. 2018;9:2542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 137. Nguyen E, Poli M, Durrant MG, Kang B, Katrekar D, Li DB, et al. Sequence modeling and design from molecular to genome scale with Evo. Science. 2024;386:eado9336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139. Camara‐Wilpert S, Mayo‐Muñoz D, Russel J, Fagerlund RD, Madsen JS, Fineran PC, et al. Bacteriophages suppress CRISPR–Cas immunity using RNA‐based anti‐CRISPRs. Nature. 2023;623:601–607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140. Liu Z‐X, Zhang S, Zhu H‐Z, Chen Z‐H, Yang Y, Li L‐Q, et al. Hydrolytic endonucleolytic ribozyme (HYER) is programmable for sequence‐specific DNA cleavage. Science. 2024;383:eadh4859. [DOI] [PubMed] [Google Scholar]
  • 141. Kreitz J, Friedrich MJ, Guru A, Lash B, Saito M, Macrae RK, et al. Programmable protein delivery with a bacterial contractile injection system. Nature. 2023;616:357–364. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from mLife are provided here courtesy of Wiley

RESOURCES